Structuring a Consumer Duty Fair Value Assessment That Withstands FCA Review

The FCA has moved past principles-based patience. Fair value assessments are now being read forensically, product by product, cohort by cohort, and the supervisors doing the reading have already seen hundreds of them. A weak assessment does not just fail; it hands the regulator a live thread to pull, often ending in mandated price changes, distribution restrictions, or a Skilled Persons review. The task is to produce an assessment that closes off intervention triggers before the regulator asks the first question.

Key Executive Takeaways

• The FCA intervenes on price when a firm cannot explain, in its own evidence, why cost-to-consumer is proportionate to the benefits actually received by each identifiable cohort.
• Benchmarking is the single most common failure point: internal margin analysis is not fair value evidence, and peer pricing without benefit comparison is worse than none.
• The assessment must show the governance route from data to decision, including what the firm considered changing and why it did not.

Start with the cohorts, not the product

Most assessments still begin with a product description and layer consumer analysis on top. That structure invites the regulator to ask why average outcomes obscure poor ones. Invert it. Define the cohorts first: new versus tenured customers, vulnerable segments, distribution channel, price paid, product usage intensity, and any legacy pricing tiers. Then assess value for each. If you cannot draw the cohorts because the data is not there, say so explicitly and set a remediation date. Silence on data gaps is read as concealment.

Build the benefit side before the cost side

Fair value is a ratio, and firms consistently over-invest in cost analysis while leaving benefits described in marketing language. The FCA wants quantified benefits: claims paid ratios, feature utilisation, servicing outcomes, retention behaviour, complaint themes by cohort. Where a benefit is contingent (breakdown cover, packaged account perks, optional protection), show utilisation rates. A benefit no cohort uses is not a benefit; it is a cross-subsidy the regulator will identify faster than you will.

Benchmark properly or not at all

Internal benchmarking against prior years shows trajectory, not value. External benchmarking against competitor price alone tells the FCA nothing about whether the market itself is delivering value. Good benchmarking triangulates: comparable products' total cost of ownership, comparable benefit delivery (not just headline features), and, where possible, outcome data such as claims acceptance rates or complaints per thousand. If a segment of your book sits materially above the market on price and at or below on benefits delivered, name it and explain the remediation path. Do not let the regulator find it.

Treat distribution as part of the price

Intermediated products fail fair value tests when the manufacturer's assessment stops at the factory gate. The total cost the customer pays, including adviser fees, platform charges, and any cross-sales, is what the FCA assesses. Manufacturers must evidence they have distributor data and have acted on outliers. "We requested the data" is not acting on it.

Show the governance trail

The assessment document should make visible: what the product committee reviewed, what challenge the board or Consumer Duty Champion raised, what options were considered (including price reductions, feature enhancements, withdrawal), and why the chosen action was proportionate. An assessment that concludes "fair value confirmed" with no evidence of options considered reads as a rubber stamp. Include the counterfactual you rejected.

What good looks like

A strong assessment is uncomfortable to read internally. It surfaces cohorts where value is marginal, sets thresholds for future intervention, and commits to specific actions with owners and dates. It treats the FCA as a second reader from page one. Weak assessments read like defence documents; strong ones read like management reports the board actually uses.

The decision in front of you now

Before your next annual cycle closes, stress-test one product against a hostile supervisory read. If your team cannot answer, with data, why the highest-paying cohort receives proportionate benefit, you have your remediation priority. Fixing it in your own assessment is materially cheaper than fixing it under a section 166.

Frequently Asked Questions

How granular should cohort analysis be?

Granular enough that no cohort receiving materially worse outcomes is hidden inside an average. In practice, that usually means tenure bands, vulnerability flags, channel, and price tier at minimum. If a cohort is too small to analyse meaningfully, say so and explain how you monitor it.

Does the FCA expect price reductions where value is marginal?

Not automatically. The regulator expects a documented, evidenced decision. Price is one lever; feature enhancement, servicing improvement, or withdrawal are others. What triggers intervention is the absence of a credible response, not the choice of response.

Can we rely on distributor attestations for fair value data?

Only if you have tested them. Attestations without sampled data or outcome monitoring are treated as unverified. Manufacturers remain accountable for total cost to the customer.

How should the board Champion engage with the assessment?

Before sign-off, not after. The Champion should have documented challenge on cohort definitions, benchmarking robustness, and the options considered. Post-hoc endorsement provides no protection.

What is the single fastest way to weaken an assessment?

Averaging. Any metric expressed only as a portfolio average invites the question of what the distribution looks like. Assume the FCA will ask, and answer in the document.